Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Published Online February 16, 2006
Science DOI: 10.1126/science.1124875

Reports

Submitted on January 11, 2006
Accepted on February 1, 2006

A Protein Farnesyltransferase Inhibitor Ameliorates Disease in a Mouse Model of Progeria

Loren G. Fong 1*, David Frost 2, Margarita Meta 3, Xin Qiao 1, Shao H. Yang 1, Catherine Coffinier 1, Stephen G. Young 1*

1 Department of Medicine/Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
2 Abbott Laboratories, Abbott Park, IL 60064, USA.
3 Department of Radiology, University of California, San Francisco, CA 94107, USA.

* To whom correspondence should be addressed.
Loren G. Fong , E-mail: lfong{at}mednet.ucla.edu
Stephen G. Young , E-mail: sgyoung{at}mednet.ucla.edu

Progerias are rare genetic diseases characterized by premature aging. Several progeroid disorders are caused by mutations that lead to the accumulation of a lipid-modified (farnesylated) form of prelamin A, a protein that contributes to the structural scaffolding for the cell nucleus. In progeria, the accumulation of farnesyl-prelamin A disrupts this scaffolding, leading to misshapen nuclei. Previous studies have shown that farnesyltransferase inhibitors (FTIs) reverse this cellular abnormality. Here, we test the efficacy of an FTI (ABT-100) in Zmpste24-deficient mice, a mouse model of progeria. The FTI-treated mice exhibited improved body weight, grip strength, bone integrity, and percent survival at 20 weeks of age. These results suggest that FTIs may have beneficial effects in humans with progeria.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Increasing the length of progerin's isoprenyl anchor does not worsen bone disease or survival in mice with Hutchinson-Gilford progeria syndrome.
B. S. J. Davies, S. H. Yang, E. Farber, R. Lee, S. B. Buck, D. A. Andres, H. P. Spielmann, B. J. Agnew, F. Tamanoi, L. G. Fong, et al. (2009)
J. Lipid Res. 50, 126-134
   Abstract »    Full Text »    PDF »
Reversible phenotype in a mouse model of Hutchinson-Gilford progeria syndrome.
H Sagelius, Y Rosengardten, E Schmidt, C Sonnabend, B Rozell, and M Eriksson (2008)
J. Med. Genet. 45, 794-801
   Abstract »    Full Text »    PDF »
Suppression of Proliferative Defects Associated with Processing-defective Lamin A Mutants by hTERT or Inactivation of p53.
B. A. Kudlow, M. N. Stanfel, C. R. Burtner, E. D. Johnston, and B. K. Kennedy (2008)
Mol. Biol. Cell 19, 5238-5248
   Abstract »    Full Text »    PDF »
A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model.
B. C. Capell, M. Olive, M. R. Erdos, K. Cao, D. A. Faddah, U. L. Tavarez, K. N. Conneely, X. Qu, H. San, S. K. Ganesh, et al. (2008)
PNAS 105, 15902-15907
   Abstract »    Full Text »    PDF »
Epidermal expression of the truncated prelamin A causing Hutchinson-Gilford progeria syndrome: effects on keratinocytes, hair and skin.
Y. Wang, A. A. Panteleyev, D. M. Owens, K. Djabali, C. L. Stewart, and H. J. Worman (2008)
Hum. Mol. Genet. 17, 2357-2369
   Abstract »    Full Text »    PDF »
A Potent HIV Protease Inhibitor, Darunavir, Does Not Inhibit ZMPSTE24 or Lead to an Accumulation of Farnesyl-prelamin A in Cells.
C. Coffinier, S. E. Hudon, R. Lee, E. A. Farber, C. Nobumori, J. H. Miner, D. A. Andres, H. P. Spielmann, C. A. Hrycyna, L. G. Fong, et al. (2008)
J. Biol. Chem. 283, 9797-9804
   Abstract »    Full Text »    PDF »
Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin.
T. Dechat, K. Pfleghaar, K. Sengupta, T. Shimi, D. K. Shumaker, L. Solimando, and R. D. Goldman (2008)
Genes & Dev. 22, 832-853
   Abstract »    Full Text »    PDF »
Eliminating the Synthesis of Mature Lamin A Reduces Disease Phenotypes in Mice Carrying a Hutchinson-Gilford Progeria Syndrome Allele.
S. H. Yang, X. Qiao, E. Farber, S. Y. Chang, L. G. Fong, and S. G. Young (2008)
J. Biol. Chem. 283, 7094-7099
   Abstract »    Full Text »    PDF »
Involvement of xeroderma pigmentosum group A (XPA) in progeria arising from defective maturation of prelamin A.
Y. Liu, Y. Wang, A. E. Rusinol, M. S. Sinensky, J. Liu, S. M. Shell, and Y. Zou (2008)
FASEB J 22, 603-611
   Abstract »    Full Text »    PDF »
Disease Progression in Hutchinson-Gilford Progeria Syndrome: Impact on Growth and Development.
L. B. Gordon, K. M. McCarten, A. Giobbie-Hurder, J. T. Machan, S. E. Campbell, S. D. Berns, and M. W. Kieran (2007)
Pediatrics 120, 824-833
   Abstract »    Full Text »    PDF »
Farnesyl transferase inhibitor resistance probed by target mutagenesis.
T. Raz, V. Nardi, M. Azam, J. Cortes, and G. Q. Daley (2007)
Blood 110, 2102-2109
   Abstract »    Full Text »    PDF »
Mechanisms of Cardiovascular Disease in Accelerated Aging Syndromes.
B. C. Capell, F. S. Collins, and E. G. Nabel (2007)
Circ. Res. 101, 13-26
   Abstract »    Full Text »    PDF »
Thematic review series: Adipocyte Biology. Lipodystrophies: windows on adipose biology and metabolism.
R. A. Hegele, T. R. Joy, S. A. Al-Attar, and B. K. Rutt (2007)
J. Lipid Res. 48, 1433-1444
   Abstract »    Full Text »    PDF »
Vascular Cell Senescence: Contribution to Atherosclerosis.
T. Minamino and I. Komuro (2007)
Circ. Res. 100, 15-26
   Abstract »    Full Text »    PDF »
Progeria of Stem Cells: Stem Cell Exhaustion in Hutchinson-Gilford Progeria Syndrome.
J. Halaschek-Wiener and A. Brooks-Wilson (2007)
J. Gerontol. A Biol. Sci. Med. Sci. 62, 3-8
   Abstract »    Full Text »    PDF »
Prelamin A Farnesylation and Progeroid Syndromes.
S. G. Young, M. Meta, S. H. Yang, and L. G. Fong (2006)
J. Biol. Chem. 281, 39741-39745
   Abstract »    Full Text »    PDF »
DNA damage responses in progeroid syndromes arise from defective maturation of prelamin A.
Y. Liu, A. Rusinol, M. Sinensky, Y. Wang, and Y. Zou (2006)
J. Cell Sci. 119, 4644-4649
   Abstract »    Full Text »    PDF »
Molecular bases of progeroid syndromes.
C. L. Navarro, P. Cau, and N. Levy (2006)
Hum. Mol. Genet. 15, R151-R161
   Abstract »    Full Text »    PDF »
Nuclear lamins: laminopathies and their role in premature ageing..
J. L. V. Broers, F. C. S. Ramaekers, G. Bonne, R. B. Yaou, and C. J. Hutchison (2006)
Physiol Rev 86, 967-1008
   Abstract »    Full Text »    PDF »
Pushing the envelope..
M. Leslie (2006)
Sci. Aging Knowl. Environ. 2006, nf14
   Abstract »    Full Text »
Improving Aging with Lipid-Lowering Drugs.
(2006)
Journal Watch Dermatology 2006, 8
   Full Text »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)